Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. Chief Executive Officer Sean P. Duffy reported an open-market sale of 14,960 shares of common stock on June 16, 2026 at an average price of $17.3604 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating it was pre-scheduled.
Following the sale, Duffy directly holds 411,861 shares of Omada Health common stock. In addition, 851,659 shares are held indirectly in family trusts for the benefit of his family members, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. Chief Financial Officer Steven L. Cook sold 6,800 shares of common stock in an open-market transaction. The sale took place on June 15, 2026 at a weighted average price of $17.2329 per share, based on multiple trades between $17.00 and $17.47.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Cook adopted on March 14, 2026, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, he directly holds 187,209 shares of Omada Health common stock.
Omada Health, Inc. Chief Accounting Officer Gracey Craig sold 6,894 shares of Common Stock on June 12, 2026 in an open-market transaction at a weighted average price of $17.4243 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. Following this transaction, Craig directly owns 9,191 Omada Health shares.
Omada Health, Inc. President Shao Wei-Li reported an open-market sale of 4,589 shares of common stock at a weighted average price of $17.2407 per share. After this transaction, Wei-Li directly holds 316,238 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.
Omada Health, Inc. held its 2026 annual stockholder meeting on June 16, 2026. Common stockholders of record as of April 20, 2026 were entitled to one vote per share.
Stockholders elected Sean Duffy and Trevor Fetter as Class I directors to serve until the 2029 annual meeting. Duffy received 18,540,089 votes for and 9,134,162 withheld, while Fetter received 18,538,042 votes for and 9,136,209 withheld, with 13,920,625 broker non-votes for each nominee.
Stockholders also ratified the appointment of Deloitte & Touche LLP as Omada Health’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41,550,689 votes for, 16,905 against, and 27,282 abstentions.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to dispose of Common stock. The filing lists 6,250 shares associated with an Exercise of Stock Options dated 06/12/2026 and 644 shares tied to Restricted Stock Units dated 06/01/2026.
OMDA filed a Rule 144 notice listing 4,589 shares of Common Stock proposed for sale. The filing lists the broker as Morgan Stanley Smith Barney LLC Executive Financial Services and indicates Restricted Stock Units as the security type with an applicable date of 06/01/2026. The notice also records prior 10b5-1 sales of 2,829 shares on 04/08/2026.
Omada Health, Inc.'s Chief Executive Officer Sean P. Duffy reported routine share dispositions in company stock. He made a bona fide gift of 9,450 shares of common stock and had 4,422 shares withheld to cover tax obligations. After these transactions, he holds 426,821 shares directly and 851,659 shares indirectly through family trusts, where he disclaims beneficial ownership except for his pecuniary interest.